Current position

J.P. Morgan Asset Management’s Cvs Health Corp (CVS) position

Reported position history, portfolio importance and verified filing changes from public SEC disclosures.

JPMorgan Chase & Co. (consolidated SEC filer)Verified through Q2 2026
Relationship snapshot

At a glance

The full verified relationship, including prior ownership episodes and exits where supported.

First reportedQ1 2015Earliest verified positive filing snapshot
Latest statusCurrent positionBased on the latest supported relationship state
Peak shares35.28MHighest verified quarter-end share count
Quarters reported24Verified quarters with shares above zero
What happened?

JPMorgan Chase & Co. (consolidated SEC filer) first reported Cvs Health Corp in Q1 2015. The reported position was increased and reduced across later filings. JPMorgan Chase & Co. (consolidated SEC filer) currently reports 22.11M shares. The latest verified filing showed: Sold 25.1% of the position.

Verified SEC history

Position over time

See the same verified relationship through reported shares, portfolio weight or reported value.

Metric

Gaps indicate periods that cannot be safely connected or where a verified corporate action changes the raw share scale. Stock price, when available, is market context and not a transaction price.

Key filing events

What changed

Latest filing plus the most meaningful reported changes. Unchanged quarters are collapsed by default.

Q2 2026
Sold 25.1% of the position−7.41M shares · 22.11M shares remained
Filing context

Quarter-end price $103.58

Q1 2026
Sold 5.4% of the position−1.68M shares · 29.53M shares remained
Filing context

Quarter-end price $70.14

Q4 2025
Sold 11.5% of the position−4.07M shares · 31.20M shares remained
Filing context

Quarter-end price $79.36

Q3 2025
Bought 31.2% more+8.40M shares · 35.28M shares reported after the change
Filing context

Quarter-end price $75.39

Q2 2025
Bought 14.7% more+3.44M shares · 26.88M shares reported after the change
Filing context

Quarter-end price $68.98

Q1 2025
Bought 68.7% more+9.54M shares · 23.44M shares reported after the change
Filing context

Quarter-end price $67.75

Portfolio importance

How important is Cvs Health Corp in JPMorgan Chase & Co. (consolidated SEC filer)’s reported portfolio?

Relative importance is measured only within the verified primary non-option reported portfolio for each quarter.

Current portfolio weight0.1%Q2 2026
Current rank#157of 7720 reported positions
Peak portfolio weight0.4%Q1 2015
Best historical rank#44Q1 2015
SEC evidence & methodology

SEC filing evidence

Market context and filing-derived values are kept separate from actual transaction prices, which 13F filings do not disclose.

Latest verified stock price$87.102026-09-22

Market context only; not an investor transaction price.

Latest filing quarter-end price$103.58Q2 2026

Derived from validated reported value and shares where supported.

Latest verified investor filingQ2 2026 · filed 2026-08-12
Open SEC filing ↗

The reported holdings and portfolio value cover JPMorgan Chase & Co.'s consolidated 13F filing, not J.P. Morgan Asset Management alone, a single fund, or the firm's total assets under management. The displayed holdings and history are bounded selections; weights use the full reported 13F value. Portfolio performance is not published, and position-level estimates remain withheld unless their evidence gates pass.